Neurocrine Biosciences (NBIX) Misses Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Neurocrine Biosciences Reports Third Quarter 2015 Results
October 29, 2015 4:01 PM EDTSAN DIEGO, Oct. 29, 2015 /PRNewswire/ --Â Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended September 30, 2015. Â For the third quarter of 2015, the Company reported a net loss of $34.4 million, or $0.40 loss per share, compared to a net loss of $15.9 million, or $0.21 loss per share, for the same period in 2014. Â For the nine months ended September 30, 2015, the Company reported a net loss of $59.6 million, or $0.71 loss per share, as compared to net loss of $41.1 million, or $0.56 loss per share, for the first nine months of last year.
The Company's... More
